🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#TumorBoardTuesday Matt Galsky Shilpa Gupta Enrique Grande Petros Grivas Sumanta K. Pal, MD, FASCO joaquim bellmunt Tom Powles Félix Guerrero-Ramos Antoni Vilaseca 16/18 📌 Would you offer TAR-210 in our case based on the phase-1 clinical trial result? #TumorBoardTuesday

#TumorBoardTuesday Matt Galsky Shilpa Gupta Enrique Grande Petros Grivas Sumanta K. Pal, MD, FASCO joaquim bellmunt Tom Powles Félix Guerrero-Ramos Antoni Vilaseca Post-TEST Question 1 Which of the following was observed with oral erdafitinib in the THOR-2 trial of FGFR+ BCG-unresponsive NMIBC?

#TumorBoardTuesday Matt Galsky Shilpa Gupta Enrique Grande Petros Grivas Sumanta K. Pal, MD, FASCO joaquim bellmunt Tom Powles Félix Guerrero-Ramos Antoni Vilaseca Post-TEST Question 2 Which of the following is likely optimal for a patient with intermediate-risk, BCG-unresponsive NMIBC harboring an FGFR3 alteration? #TumorBoardTuesday

Emre Yekedüz Matt Galsky Shilpa Gupta Enrique Grande Petros Grivas Sumanta K. Pal, MD, FASCO joaquim bellmunt Tom Powles Félix Guerrero-Ramos Antoni Vilaseca #TumorBoardTuesday 🙏Thank you so much Yüksel Ürün & Emre Yekedüz for a very enlightening🗣️on🎯💊for early-stage bladder cancer 📢And staying with the early-stage theme, join us next week 05-13-25 as Narjust Florez, MD, FASCO & Mihaela Aldea 🗣️the use of IO in earlier stage #NSCLC

Yüksel Ürün ASCO Dear Prof. Yüksel Ürün, I’m truly grateful for your kind words and support. It’s a great privilege for us to have inspiring leaders like you in our community.

Final MAGNITUDE 📢 In mCRPC with BRCA mutations: Niraparib to Abiraterone = ⬇️ progression risk by 47% ⏳ rPFS: 19.5 vs 10.9 months 🧬 No benefit in non-HRR pts ✅ Confirmed the biomarker-driven benefit! European Urology Oncology OncoAlert Advanced Prostate Cancer Consensus Conference Elena Castro AttardLab

DESTINY-Breast11 (Phase 3): Enhertu followed by THP showed a significant boost in pCR with a better safety profile vs ddAC-THP. An anthracycline-free neoadjuvant option that may reshape standard care. #breastcancer OncoAlert

This #BladderCancerAwarenessMonth, Highlighting ADC therapies in Muscle-Invasive Bladder Cancer offering new hope for better outcomes. #BladderCancer #Oncology #ADC #LARVOL #MIBC #CancerResearch #OncologyInsights #CancerData #CancerCare #ClinicalTrial Enrique Grande

🌟 #IUCS25 Poll – Treatment Breaks in mUC🌟 🧔‍♂️ 65 y/o man w/ metastatic urothelial carcinoma, lung mets 💉 1L EV + pembro, ECOG 0 ✅ After 6 mo → CRR 🤝 He’s tolerating tx well, but asks for a break to enjoy time. 💬 Assuming you can resume upon PROG, what would you do?

📍We proudly celebrate Prof. Christian Rolfo for being awarded the honorary title of Doctor Honoris Causa by the University of Buenos Aires! 🎓✨ At ISLB, we are honored to have his leadership guiding the advancements and shaping the future of liquid biopsy. His dedication

Clinically very relevant question!

🌟Treatment Breaks in mUC What do you prioritize when patients ask for a break after a deep response?🌟 Clinical reality meets shared decision-making. 👇 Join the poll & let’s learn from global practice! Neeraj Agarwal, MD, FASCO Enrique Grande Petros Grivas Giuseppe Banna Laurence Albiges

The OncoAlert🚨Newsletter Now Out Covering May 2-8, 2025 REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing:🇺🇸💊✅ ✅Association between risk-reducing surgeries and survival in young BRCA carriers with #BreastCancer Eva Blondeaux Matteo Lambertini, MD PhD

In oligomet castration sensitive prostate cancer with bone mets, adding ☢️Ra223 to ⚡️SABR MDT did not improve ❌PFS (11.8 vs 10.5 mo, HR 1.42, P=.24). 🧬HiRi mutations (ATM, BRCA1/2, RB1, TP53) linked to worse outcomes; 🧫TCR diversity predicted better PFS. ❗️Biomarkers matter.

FDA grants accelerated approval to avutometinib + defactinib combo for KRAS-mutated recurrent low-grade serous ovarian cancer after prior therapy. U.S. FDA OncoAlert fda.gov/drugs/resource…

Cancer rising in the young! NIH National Cancer Institute ASCO OncoAlert nih.gov/news-events/ne…

Big salute to Suresh S. Ramalingam, MD, FASCO named to TIME100 Health 2025 for transforming lung cancer care. Science that saves lives. ASCO IASLC

POTOMAC trial- Durvalumab + BCG shows positive results for DFS in high-risk NMIBC vs BCG alone. sasanlimab (CREST) also had an EFS advantage here: HR 0.68. Consistent results in early disease is compelling. IO tox is relevant in risk/benefit ratio. astrazeneca.com/media-centre/p…

NEWS FROM INDUSTRY: SOURCE Astra Zeneca POTOMAC Update Astra Zeneca reports that the POTOMAC Phase III trial demonstrated that adding one year of durvalumab to standard Bacillus Calmette-Guérin (BCG) induction and maintenance therapy significantly improved disease-free survival

Science is saving lives. But the journey isn’t over—early detection, fair access, and better treatments still matter. #Cancer #Oncology #HealthEquity U.S. FDA